Randomized Phase III Trial of Topotecan Following Carboplatin and Paclitaxel in First-line Treatment of Advanced Ovarian Cancer: A Gynecologic Cancer Intergroup Trial of the AGO-OVAR and GINECO-Reference-Cited by-同舟云学术

Randomized Phase III Trial of Topotecan Following Carboplatin and Paclitaxel in First-line Treatment of Advanced Ovarian Cancer: A Gynecologic Cancer Intergroup Trial of the AGO-OVAR and GINECO

Published:2006-08-02 Issue:15 Volume:98 Page:1036-1045
ISSN:1460-2105
Container-title:JNCI: Journal of the National Cancer Institute
language:en
Short-container-title:

Author:

Pfisterer Jacobus,Weber Béatrice,Reuss Alexander,Kimmig Rainer,du Bois Andreas,Wagner Uwe,Bourgeois Hugues,Meier Werner,Costa Serban,Blohmer Jens-Uwe,Lortholary Alain,Olbricht Sigrid,Stähle Anne,Jackisch Christian,Hardy-Bessard Anne-Claire,Möbus Volker,Quaas Jens,Richter Barbara,Schröder Willibald,Geay Jean-François,Lück Hans-Joachim,Kuhn Walther,Meden Harald,Nitz Ulrike,Pujade-Lauraine Eric

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

http://academic.oup.com/jnci/article-pdf/98/15/1036/7687413/djj296.pdf

Reference36 articles.

1. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med1996 ; 334 : 1 –6.

2. Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst2000 ; 92 : 699 –708.

3. Piccart MJ, Bertelsen K, Stuart G, Cassidy J, Mangioni C, Simonsen E, et al. Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. Int J Gynecol Cancer2003 ; 13 (Suppl 2): 144 –8.

4. du Bois A, Luck HJ, Meier W, Adams HP, Mobus V, Costa S, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst2003 ; 95 : 1320 –9.

5. Neijt JP, Engelholm SA, Tuxen MK, Sorensen PG, Hansen M, Sessa C, et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol2000 ; 18 : 3084 –92.

Cited by 179 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Maintenance Chemotherapy in Patients with Platinum-Sensitive Relapsed Epithelial Ovarian Cancer after Second-Line Chemotherapy;Journal of Clinical Medicine;2024-01-18

2. Maintenance therapy for newly and recurrent epithelial ovarian cancer: current therapies and future perspectives;Current Opinion in Obstetrics & Gynecology;2023-12-04

3. Suboptimal Surgery and Oncologic Outcomes in Women with Ovarian Cancer: An Analysis of Predictive Factors;2023-08-24

4. Toxicity and therapy outcome associations in LIG3, SLCO1B3, ABCB1, OPRM1 and GSTP1 in high‐grade serous ovarian cancer;Basic & Clinical Pharmacology & Toxicology;2023-04-06

5. Homologous Recombination Deficiency in Ovarian Cancer: from the Biological Rationale to Current Diagnostic Approaches;Journal of Personalized Medicine;2023-02-02